A prospective, randomized, open-label clinical trial evaluating the effect of sarpogrelate hydrochloride on skin perfusion pressure in hemodialysis patients with arteriosclerosis obliterans
Not Applicable
Recruiting
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000003597
- Lead Sponsor
- Department of Internal Medicine, Tokai University School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with revascularization 2)Patients who is taking antiplatelet agents excluding low-dose aspirin and/or thienopyridine derivatives 3)Patients with warfarin 4)Patients with coronary artery disease and/or cerebrovascular disease within three months 5)Patients with bleeding or bleeding tendency 6)Patients with severe hepatic dysfunction and/or cardiac dysfunction 7)Patients with malignancy 8)Pregnant or lactating women, or women who wish to become pregnant 9)Patients with allergy to sarpogrelate hydrochloride 10)Patients who were not suitable for this trial judged by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in SPP
- Secondary Outcome Measures
Name Time Method Improvement of symptoms of ASO Change in ABI Adverse event